Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tolinapant |
| Synonyms | |
| Therapy Description |
Tolinapant (ASTX-660) is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (PMID: 40353748, PMID: 31900279). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tolinapant | ASTX660|ASTX 660|ASTX-660 | SMAC Mimetic 8 | Tolinapant (ASTX-660) is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (PMID: 40353748, PMID: 31900279). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04155580 | Phase I | Tolinapant Decitabine and Cedazuridine + Tolinapant | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
| NCT02503423 | Phase Ib/II | Tolinapant | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Active, not recruiting | USA | ITA | HUN | GBR | FRA | ESP | CAN | BEL | 0 |